ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism

Introduction

Endothelial dysfunction is one of the precursor key steps in the development of atherosclerosis in diabetic subjects. Decreased nitric oxide (NO) production, increased oxidative stress and impaired function of endothelial progenitor cells are the main mechanisms involved in the accelerated atherosclerotic process observed in patients with type 2 diabetes (T2D). Diabetes mellitus and heart failure are associated with diminished release of NO into the arterial wall because of impaired synthesis or excessive oxidative degradation (1).

Diabetic patients present more frequently with acute pulmonary edema than non-diabetics, have more often acute coronary syndrome as precipitating factors of acute heart failure, and multiple co-morbidities such as renal dysfunction, arterial hypertension, anemia and peripheral vascular disease (2).

High incidence of diastolic dysfunction in asymptomatic diabetics is correlated with the duration of diabetes, HbA1c levels, obesity indices and diabetic microangiopathies (3). Moreover, patients with diabetes compared with those without diabetes were significantly older and more often had other cardiovascular risk factors, signs of heart failure and high the Global Registry of Acute Coronary Events (GRACE) score at admission (4). More intensive glycemic control in patients with T2D did not reduce the occurrence of heart failure events (5). Current evidence indicates the presence of several biochemical and molecular changes associated with diabetes that lead to diastolic dysfunction or American Heart Association stage B heart failure (6). In experimental animal model the increased C-reactive protein expression exacerbated left ventricular dysfunction after myocardial infarction (7).

Elevated circulating N-terminal pro brain natriuretic peptide (NT-proBNP) in T2D is a strong predictor of the excess overall and cardiovascular mortality independent of conventional cardiovascular risk factors (8). NT-proBNP is of prognostic value that discriminates acute coronary syndrome patients at higher risk (9).

The aim of this study was to demonstrate the interrelation between serum NT-proBNP (a biomarker of heart failure), NO (a biomarker of endothelial dysfunction) and C-reactive protein (an inflammatory biomarker) in T2D without clinical evidence of heart failure.

Materials and Methods

This study was done in the Department of Pharmacology, College of Medicine, Al-Mustansiriya University in cooperation with the Layla Qasim Diabetic Center in Erbil- Kurdistan, and the Laboratories of Specialized Center for Cardiac Surgery, Ibn Al-Bitar Hospital in Baghdad. Patients with T2D referred to the Layla Qasim Diabetic Center in Erbil, Kurdistan-Iraq were enrolled in this study. The study approved by the scientific committee at Hawler Medical University, College of Pharmacy. Written informed consent was obtained from each participant to donate a sample of venous blood for diagnostic biochemical tests. The criteria of inclusion was the presence of T2D. The criteria of exclusion included clinical evidences of heart failure and/or ischemic heart, and the presence of other diabetic complications.

A total of 75 (25 males and 50 females) participants fulfilled the inclusion criteria. Non diabetic subjects (12 males and 13 females) were also included in this study. The anthropometric measurements, including weigh, height and the calculated body mass index (weight/height2), fasting and HbA1c% were determined. Fasting venous blood samples were obtained from the participants and the sera were separated for determination of C-reactive protein, NT-proBNP and NO.

Serum proBNP levels were determined in the Laboratories of Specialized Center for Cardiac Surgery, İbn Al-Bitar Hospital using the technique of Enzyme Linked Fluorescent Assay (VIDAS NT-proBNP automated test for use on the VIDAS instrument). The principle of this assay is a one step immunoassay sandwich method with a final fluorescent detection (ELFA) and the range of measurement is 20-25000 pg/ml). Levels below 100 pg/ml indicate no heart failure, 100-300 pg/ml suggest the presence of heart failure, >300 indicate mild heart failure, >600 ml indicate moderate heart failure and >900 pg/ml indicate severe heart failure.

Serum C-reactive protein (LINEAR chemical SL Company, Barcelona, Spain) determined qualitatively using the cut-off level of ≥6 mg/L as a positive test indicating the presence of inflammation.

Serum NO was determined as described below (10): - briefly, 500 μl of serum was added to 50 μl HCl (6.5 M) and 50 μl sulfanilic acid (37.5 mM). After incubation for 10 minutes, 50 μl naphthylethylenediamine dihydrochloride (12.5 mM) was added and was incubated for a further 30 minutes and then centrifuged for 10 minutes at 1000 g. The absorbance at 540 nm was immediately recorded. The concentration of NO as nitrate/nitrite was calculated from the standard curve of lithium nitrate.

Statistical Analysis

The results are expressed as absolute number, percent, mean ± SD. The data analyzed using the student’s t-test (one paired, two tailed), simple correlation test and odd ratio taking the p≤0.05 as lowest limit of significance.

Results

Table 1 shows the characteristics of the study. The mean age of the patients was 41 years and the majority of the patients had family history of diabetes. The median duration of diabetes was 8 years and all patients were poorly controlled by the evidence of HbA1c% which was more than 7% (Table 1). The majority of patients were overweighed and only 10.7% (8 out of 75) were obese class I (Table 1). Serum NT-proBNP levels were ranged from 10 to 8368 pg/ml and 8 (10.7%) patients had high serum level of NT-proBNP (≥600 pg/ml) indicating the presence of moderate to severe heart failure (Table 2). Figure 1 shows significantly low serum NO (60.98±30.75 µmol, p<0.001) levels in patients compared with healthy subjects (120.3±12.5 µmol). Serum NO significantly and inversely correlated with serum NT-proBNP levels in patients with T2D mellitus (Figure 2). Further analysis revealed that 14 out of 75 (18.7%) patients had positive C-reactive protein, seven of them (50%) showed significant high serum level of NT-proBNP (≥600 pg/ml). Patients with positive C-reactive protein had significantly lower serum NO level compared with those expressed negative C-reactive protein reaction (Table 3). The other determinants are duration of disease, HbA1c%, fasting serum glucose did not show significant differences regarding the positive C-reactive test.

Discussion

This study shows that insidious heart failure is detected in T2D by the measurement of serum NT-proBNP levels. This biomarker inter-relates with C-reactive protein and nitrogen species indicating that these markers are involved in heart failure associated with T2D. In diabetes, coronary artery disease and cardiomyopathy are the most frequent and insidious complications (11). Diabetic cardiomyopathy is characterized by left ventricular diastolic dysfunction that can be detected in 52%-60% of well-controlled subjects. Hyperglycaemia induce myocardial inflammation and is associated with decreased NO levels as well as worsening in the endothelial function (12). The results of this study are in agreement with those of another study that showed increased serum NT-proBNP and C-reactive protein levels in idiopathic and dilated cardiomyopathy (13). Moreover, increased C-reactive protein and nitrogen species that demonstrated in congestive heart failure are due to dilated cardiomyopathy in dogs (14). Metabolic dysfunction occurring in diabetes explained the increased NT-proBNp level which indicated heart failure that resulted from diabetic cardiomyopathy. In diabetic heart, inhibition of glycolytic enzymes disturb the flux of substrate through the glycolytic pathway and leads to the diversion of glycolytic intermediate substrate through another pathway, which in turn mediates the onset of diabetic cardiomyopathy (15). Endothelial dysfunction represented by low NO and high peroxynitrite levels is demonstrated in this study. A recent study focused on the role of hyperglycemia in inducing oxidative stress and leading to changes in cellular signaling manifested by production of several vasoactive and cardioactive factors. Therefore, dysfunction of both vascular endothelial cells and cardiomyocytes play a role in the pathogenesis of diabetic cardiomyopathy (16). Accordingly, the endothelial dysfunction occurring in T2D is associated with changes in vas-regulation (demonstrated by low serum NO), inflammatory activation (demonstrated by positive C-reactive protein test), and altered cardiac cell function (demonstrated by high serum NT-proBNP level) (17). It is concluded that increased serum NT-proBNP level in the absence of clinically diagnosed heart failure is observed in T2D and it may serve as a diagnostic biomarker of insidious heart failure. The inflammatory marker inter-relates with biomarkers of heart failure and vascular endothelial dysfunction.

Acknowledgments

The authors expressed their thanks to Dr. Ahood Khaleel İbrahim, Department of Laboratories, İbn Al-Bitar Specialized Center for Cardiac Surgery for her kindly assistance.

Conflicts of Interest

There are no conflicts of interest.

References

1.    Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function.  Curr Vasc Pharmacol. 2012;10:4-18.
2.    Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, Meas T, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol. 2012;157:108-113.
3.    Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res 2011;2:213-222.
4.    Érlikh AD, Gratsianski? NA; Participants of the RECORD registry. [Acute coronary syndromes in hospitalized patients with diabetes. Data from the RECORD registry]. Kardiologiia 2011;51:16-21.
5.    Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, Macdonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. Am Heart J. 2011;162:938-948.
6.    Dhingra R, Vasan RS. Diabetes and the risk of heart failure. Heart Fail Clin 2012;8:125-133.
7.    Takahashi T, Anzai T, Kaneko H, Mano Y, Anzai A, Nagai T, Kohno T, Maekawa Y, Yoshikawa T, Fukuda K, Ogawa S. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2010; 99:1795-1804.
8.    Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006;49:2256-2262.
9.    Weber M, Bazzino O, Navarro Estrada JL, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol. 2008;51:1188-1195.
10.    Newaz MA, Yousefipour Z, Nawal N, Adeeb N. Nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats: Antioxidant protection by gamma-tocotrienol. J Physiol Pharmacol. 2003;54:319-327.
11.    Fragasso G, Palloshi A, Bassanelli G, Steggerda R, Montano C, Margonato A. Heart disease and diabetes: from pathophysiology to therapeutic options. Ital Heart J 2004;5:4-15.
12.    Seferovi? PM, Lali? NM, Seferovi? JP, Joti? A, Lali? K, Risti? AD, Simeunovi? D, Radovanovi? G, Vujisi?-Tesi? B, Ostaji? MU. Diabetic cardiomyopathy: old disease or new entity? Srp Arh Celok Lek. 2007;135:576-582.
13.    Zhao P, Zhang J, Yin XG, Maharaj P, Narraindoo S, Cui LQ, Tang YS.  The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy.  Life Sci. 2013;92:633-638.
14.    Cunningham SM, Rush JE, Freeman LM. Systemic inflammation and endothelial dysfunction in dogs with congestive heart failure. J Vet Intern Med. 2012;26:547-557.
15.    Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2014;19:35-48.
16.    Mortuza R, Chakrabarti S. Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy. Heart Fail Rev. 2014;19:75-86.
17.    Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJ, Stehouwer CD, Smulders YM, van Hinsbergh VW. Endothelial dysfunction in (pre)diabetes: Characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord. 2013;14:39-48.